Scarica l'app Stockscreener
0.734
3.38%
0.024
Dopo l'orario di chiusura:
.74
0.006
+0.82%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SCYX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.71
Aprire:
$0.7261
Volume 24 ore:
46,996
Relative Volume:
0.30
Capitalizzazione di mercato:
$28.64M
Reddito:
$135.87M
Utile/perdita netta:
$72.20M
Rapporto P/E:
0.5169
EPS:
1.42
Flusso di cassa netto:
$45.09M
1 W Prestazione:
-3.42%
1M Prestazione:
+0.55%
6M Prestazione:
-32.04%
1 anno Prestazione:
-66.94%
Intervallo 1D:
$0.726
$0.738
Intervallo di 1 settimana:
$0.7008
$0.7726
Portata 52W:
$0.66
$2.26
Scynexis Inc Stock (SCYX) Company Profile
Nome
Scynexis Inc
Settore
Telefono
201-884-5485
Indirizzo
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Confronta SCYX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
0.734 | 27.70M | 135.87M | 72.20M | 45.09M | 1.42 |
|
ZTS
Zoetis Inc
|
153.45 | 67.31B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.74 | 45.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.75 | 43.35B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.58 | 18.68B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
305.61 | 13.44B | 2.99B | 1.21B | 1.13B | 25.06 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-01-22 | Iniziato | Guggenheim | Buy |
| 2021-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-11 | Aggiornamento | Needham | Hold → Buy |
| 2018-06-27 | Iniziato | Maxim Group | Buy |
| 2017-10-24 | Iniziato | Guggenheim | Buy |
| 2017-07-10 | Iniziato | ROTH Capital | Buy |
| 2017-05-09 | Downgrade | Needham | Buy → Hold |
| 2017-03-03 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-20 | Iniziato | H.C. Wainwright | Buy |
| 2016-10-07 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2016-10-03 | Ripresa | Brean Capital | Buy |
| 2016-08-17 | Iniziato | Guggenheim | Buy |
| 2016-08-09 | Reiterato | Needham | Buy |
| 2016-08-09 | Aggiornamento | WBB Securities | Speculative Buy → Buy |
| 2016-03-28 | Iniziato | Brean Capital | Buy |
| 2015-12-29 | Iniziato | WBB Securities | Speculative Buy |
| 2015-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2015-06-10 | Iniziato | Needham | Buy |
| 2014-05-29 | Iniziato | Canaccord Genuity | Buy |
| 2014-05-29 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Scynexis Inc Borsa (SCYX) Ultime notizie
Is SCYNEXIS Inc. a good long term investmentFree Investment Risk Control - Autocar Professional
What drives SCYNEXIS Inc. stock priceUnmatched market performance - jammulinksnews.com
What analysts say about SCYNEXIS Inc. stockUnstoppable profit momentum - Autocar Professional
SCYNEXIS Inc. Stock Analysis and ForecastFast-track wealth growth - Autocar Professional
Is ATH.PRA a good long term investmentSkyrocketing returns - Jammu Links News
What makes SCYNEXIS Inc. stock price move sharplyTop Analyst Picks - Newser
Why SCYNEXIS Inc. stock attracts strong analyst attentionGrowth Stock Monitor - Newser
How SCYNEXIS Inc. stock performs during market volatilityFree Stock Market Analysis Courses - Newser
Scynexis Inc (SCYX) Stock: A Year of Highs and Lows in the Market - investchronicle.com
SCYNEXIS Holds Annual Meeting, Re-elects Directors - The Globe and Mail
SCYNEXIS Faces Nasdaq Delisting Notice for Stock Price - TipRanks
Millennium Management LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Squarepoint Ops LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Jane Street Group LLC Buys New Holdings in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) & SCYNEXIS (NASDAQ:SCYX) Head-To-Head Survey - Defense World
Biosergen taps antifungal expert as board member - Biostock
Northern Trust Corp Has $186,000 Stake in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Scynexis resumes dosing in Phase III MARIO study after lengthy delay - MSN
SCYNEXIS resumes Phase 3 antifungal study after FDA lift By Investing.com - Investing.com South Africa
SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold - Insider Monkey
Scynexis resumes patient dosing in Phase 3 MARIO study - TipRanks
SCYNEXIS Resumes Patient Dosing In Phase 3 MARIO Study - marketscreener.com
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX St - GuruFocus
GSK Involved in SCYNEXIS's Phase 3 Study Milestone Dispute | GSK Stock News - GuruFocus
SCYNEXIS resumes Phase 3 antifungal study after FDA lift - Investing.com Australia
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX Stock News - GuruFocus
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study - The Manila Times
SCYNEXIS Restarts Critical Phase 3 Trial for Life-Threatening Infection, Faces $30M GSK Payment Battle - Stock Titan
SCYNEXIS Faces Challenges Amidst Antifungal Developments - TipRanks
Scynexis Inc Azioni (SCYX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):